TOI — The Oncology Institute, Inc.

Summary of The Oncology Institute Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Revenue: Q3 revenue reached $137 million, a 23% increase year-over-year, driven by a 42% growth in the Pharmacy business and a 13% increase in fee-for-service revenue.
• Adjusted EBITDA: Loss of $3.5 million, an improvement of $4.7 million from Q3 2024. The company achieved its first month of adjusted EBITDA profitability in September 2025.
• Gross Profit: Total gross profit was $18.9 million, with a gross margin of 13.9%. Normalized gross profit, excluding a $1.8 million reserve for fee-for-service revenue, would have been $20.7 million (15.2% margin).
• Cash Position: Ended the quarter with $27.7 million in cash and $86 million in convertible debt maturing in 2027. Cash flow from operations was negative $27.8 million, reflecting investments in drug inventory.

2. Strategic Updates and Business Highlights

• Capitation Model Expansion: Significant progress in Florida with 40,000 delegated capitated lives under management, and plans to expand this relationship with Elevance Health.
• Pharmacy Business Growth: Pharmacy revenue reached $75.9 million, up 57.4% year-over-year, attributed to higher prescription volumes and improved pharmacy attachment rates.
• AI Initiatives: Implementation of AI in revenue cycle management and prior authorization processes is expected to enhance operational efficiencies and reduce costs significantly.
• Cybersecurity Incident: A recent cybersecurity incident at a key vendor temporarily affected billing for fee-for-service claims, but the company managed to minimize operational disruptions.

3. Forward Guidance and Outlook

• 2025 Revenue Guidance: Increased from $460-$480 million to $495-$505 million.
• Adjusted EBITDA Guidance: Revised to a loss of $13 million to $11 million for the full year, indicating a potential breakeven or slight profitability in Q4 2025.
• Free Cash Flow: Expected to be positive in Q4 2025, with full-year positive free cash flow anticipated in mid-2026.

4. Bad News, Challenges, or Points of Concern

• Cybersecurity Incident: Although managed effectively, the incident may impact collections in late Q4 and early Q1.
• Fee-for-Service Revenue Reserve: A $1.8 million reserve for potential bad debt was established, which impacted reported adjusted EBITDA.
• Market Pressures: Concerns regarding changes in managed care plans and their impact on margins and utilization rates, particularly in light of broader healthcare policy changes.

5. Notable Q&A Insights

• Sustainability of Profitability: Management expressed confidence in maintaining profitability following the first month of adjusted EBITDA positivity in September, with expectations for breakeven in Q4.
• PMPM Trends: The PMPM (per member per month) rates for new contracts are expected to remain stable, with contractual escalators in place for future increases.
• Impact of ACA Changes: Management believes that potential changes related to the ACA will not significantly impact their patient population, as most patients are already in capitated arrangements.
• Pharmacy Growth Drivers: The strong growth in pharmacy revenue is attributed to efforts to minimize leakage and improve script attachment rates, although management does not expect to sustain such high growth rates sequentially into Q4.

This summary encapsulates the key aspects of The Oncology Institute's Q3 2025 earnings call, highlighting both achievements and challenges faced by the company.